secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001683168-23-003214
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Q1 net loss $3.6M; cash $9.0M; Phase 1 trial with AgonOx expected Q2 2023
------------------------------------------------------------------------------

- Net loss of $3.6M ($3.15 per share) vs $2.6M ($2.34 per share) in Q1 2022.
- Cash at March 31, 2023: $9.0M, down from $11.8M at Dec 31, 2022; subsequent equity offering raised ~$1.7M net.
- R&D expenses $2.1M (+35% YoY); G&A $1.5M (+39% YoY).
- Expects to commence Phase 1 ACT trial with partner AgonOx by end of Q2 2023.
- Cash expected to fund operations into Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823003214/0001683168-23-003214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823003214/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-003214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer